New regulations on drug trade in Guangdong Province hinder the implementation of cheese in pharmaceutical enterprises

2013-05-21 source: Although the Securities Times has expected stricter drug bidding, the pharmaceutical industry was surprised by a "relevant rules on drug trading in Guangdong Province (Draft for comments)" Under this influence, yesterday's pharmaceutical stocks including xinlitai, Tonghua Dongbao, China Resources Shuanghe and Lizhu group all fell sharply On May 17, Guangdong Provincial Department of Health issued five draft of drug trade rules and supporting documents The draft provides comprehensive regulations on basic drugs, non basic drugs, drug purchase and distribution, transaction settlement, etc Guangdong health department intends to reduce the false high price of drugs through this move, and requires relevant units to submit modification opinions before Friday According to the sorting out of China Merchants Securities, Guangdong Pharmaceutical bidding will eventually establish a centralized third-party pharmaceutical electronic trading platform across the province, implementing "online bidding, online trading, online payment, online financing, online supervision", which is the industry's "drug exchange mode" Under this bidding mode, the traditional separation mode of bidding and procurement will change, and the group purchase caused by joint procurement will also test the pharmaceutical enterprises In fact, before the release of the above-mentioned draft, the Department of health of Guangdong Province held a tender finalization meeting on May 13 to make arrangements for the finalization of the draft It takes about one week before and after the release of the draft for comments to the relevant units to submit the modification opinions The reporter noted that the industry had a lot of disagreements on the draft for comment released by Guangdong this time, and the dissenting voices thought that the draft would have a substantial impact on the pharmaceutical industry, especially the provisions on "basic drugs without quality level" attracted a lot of controversy "The online bidding model of drug bidding remains to be discussed The previous low-cost model in Anhui has proved to be less successful, while the Guangdong model is only the continuation of the Anhui model, and there should be a correction process later." Jiang Guangce, chairman of Tibet Dechuan investment, told reporters yesterday that once Guangdong's drug bidding was carried out according to the content of the draft, it would not rule out the possibility of drug capsules appearing again in the pharmaceutical industry In the bidding process, pharmaceutical companies can only press costs on raw materials, especially for non exclusive varieties without bargaining power It is understood that there are nearly 20 different modes of medical bidding, such as Anhui mode, Nanjing mode, Fujian mode and Henan mode Among them, Anhui model was introduced in August 2010, and the industry summarized the model as "only low price is to take" Relevant people of China Pharmaceutical Enterprise Management Association have publicly questioned the model In the subsequent operation, Anhui model is still controversial The Guangdong drug bidding is considered as the continuation of Anhui model There are not a few institutions that hold similar views with Jiang Guangce According to the research of CIC securities, the overall impact of drug bidding rules in Guangdong Province on the pharmaceutical industry is more negative, but there are big obstacles in the implementation of the rules, which will not be able to be smoothly promoted in the future The head of a pharmaceutical company in Guangzhou also expressed similar views to reporters yesterday According to the person, the bidding is better than the quality control in price control, which may lead to profit seeking behavior of some pharmaceutical companies in the industry In practice, drug quality and price are very important for patients Although he doesn't agree with the one size fits all behavior of Guangdong drug bidding for the pharmaceutical industry, Jiang Guangce believes that the reform will be a great boon for pharmaceutical companies with exclusive varieties China Merchants Securities also believes that enterprises with exclusive varieties and quality advantages, as well as enterprises with good bid price maintenance, will gain comparative competitive advantage, while the competition for generic drugs tends to be fierce In the view of CIC securities, Tianshi, Kangyuan pharmaceutical, Enhua pharmaceutical, Shuanglu pharmaceutical, Changchun hi tech, Xinhua medical and other companies are the beneficiaries of Guangdong Pharmaceutical bidding For these enterprises, the impact of this round of bidding is "hollow and long" In fact, drug bidding itself is a double-edged sword Guangdong drug bidding is more like a top-down shuffling of the pharmaceutical industry at the government level The artificial price adjustment of the government and the independent price negotiation of pharmaceutical enterprises will form a long-term game